Takayuki Asato

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Makoto Nishio, Tatsuya Yoshida, Toru Kumagai et al. · Journal of Thoracic Oncology · 2020 · 68 citations

Medicine, Oncology, Pharmacotherapy +12

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Kaoru Kubota, Hiroshige Yoshioka, Fumihiro Oshita et al. · Journal of Clinical Oncology · 2017 · 50 citations

Medicine, Oncology, Pharmacology +17

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

Hiroyoshi Suzuki, Hiroji Uemura, Atsushi Mizokami et al. · Cancer Medicine · 2019 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Brigatinib in Japanese patients with <i>ALK</i>‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa et al. · Cancer Science · 2023 · 14 citations · Full text

Medicine, Oncology, Pharmacology +15

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Yung‐Jue Bang, Toshimi Takano, Chia‐Chi Lin et al. · Cancer Research and Treatment · 2017 · 13 citations · Full text

Medicine, Oncology, Pharmacology +13